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ABSTRACT
IMPORTANCE: Patients using prescription opioid are embedded in a network due
provider-sharing and living in the same community. As a result, they may exert
influence on each other’s treatment preferences and share attitudes towards
prescription opioid use and misuse.
OBJECTIVE: To determine patient characteristics associated with the observed
pattern of shared prescribers in a network and identify influential patients in the
network.
DESIGN, SETTING, AND PARTICIPANTS: We conducted a cross-sectional
network-based study using the Rhode Island (RI) Prescription Drug Monitoring
Program (PDMP) data for the 2015 calendar year. All patients who filled at least one
opioid prescription at a retail pharmacy were eligible. The analysis was limited to
patients who were on a stable opioid regimen and used only one source of payment,
and filled only one type of opioid medication (oxycodone, hydrocodone or
buprenorphine/naloxone) from ≥ 3 prescribers, and visited ≥ 3 pharmacies during the
year. To minimize the influence of less relevant network connections, we excluded
institutional providers and providers who issued opioid prescriptions to ≤ 6 patients.
We applied social network analysis (SNA) methods to a sample of 372 patients
connected to each other through provider-sharing. We used the exponential random
graph model (ERGM) assuming conditional dyadic independence to examine the
relationship between patient attributes and the likelihood of forming network ties.
Homophily was defined as the tendency of patients to associate with others who have
similar characteristics. Three centrality measures (degree, closeness, and betweenness)

were used to identify patients with potential influence in the opioid prescription
network.
MAIN OUTCMES AND MEASURES: We provide a visual and descriptive
characterization of the network, used centrality measures to identify influential
patients, and ERGM to assess homophily and differential homophily.
RESULTS: The mean age of patients included in the analysis was 51 years; 53%
were female; 57% took oxycodone, 34% took hydrocodone and 9% took
buprenorphine/naloxone. On average, 53% of patients received less than 50 morphine
milligram equivalents (MME) daily, and the mean (standard deviation [SD]) number
of opioid prescriptions per patient was 14.4 (6.6). Sixty-four percent of patients had
commercial insurance, 28% had Medicaid, 5% had Medicare, and almost 2.5% used
cash payment only. All three centrality measures were in agreement on the
identification of the most influential patient in the opioid prescription network but
overall correlation between the measures was low. After controlling for the main
effects in the ERGM model, homophily was associated with age group, method of
payment, number and type of opioid prescription filled, mean daily MME, and number
of providers seen.
CONSLUSIONS: Characteristics of patients in an opioid prescription network may
influence which provider they choose and which patients they are connect to through
provider sharing. Interventions targeted at influential patients in the network may have
potential to influence social norms around the use and misuse of prescription opioids
that may lead to reductions in prescription opioid-related overdose deaths.
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PREFACE
This thesis is written in the manuscript format, and is comprised of a single
manuscript, which applied network analysis to advance our understanding of an opioid
prescription network in the state of Rhode Island. We propose approaches to identify
and target influential patients for interventions to alter social norms around opioid
misuse. Its focus is on the application of the methods and it is written for a nonstatistical audience. A more statistical discussion of essential concepts is presented in
the Technical Appendix.
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ABSTRACT
IMPORTANCE: Patients using prescription opioid are embedded in a network due to
provider-sharing and living in the same community. As a result, they may exert
influence on each other’s treatment preferences and share attitudes towards
prescription opioid use and misuse.
OBJECTIVE: To determine patient characteristics associated with the observed
pattern of shared prescribers in a network and identify influential patients in the
network.
DESIGN, SETTING, AND PARTICIPANTS: We conducted a cross-sectional
network-based study using the Rhode Island (RI) Prescription Drug Monitoring
Program (PDMP) data for the 2015 calendar year. All patients who filled at least one
opioid prescription at a retail pharmacy were eligible. The analysis was limited to
patients who were on a stable opioid regimen and used only one source of payment,
and filled only one type of opioid medication (oxycodone, hydrocodone or
buprenorphine/naloxone) from ≥ 3 prescribers, and visited ≥ 3 pharmacies during the
year. To minimize the influence of less relevant network connections, we excluded
institutional providers and providers who issued opioid prescriptions to ≤ 6 patients.
We applied social network analysis (SNA) methods to a sample of 372 patients
connected to each other through provider-sharing. We used the exponential random
graph model (ERGM) assuming conditional dyadic independence to examine the
relationship between patient attributes and the likelihood of forming network ties.
Homophily was defined as the tendency of patients to associate with others who have
similar characteristics. Three centrality measures (degree, closeness, and betweenness)
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were used to identify patients with potential influence in the opioid prescription
network.
MAIN OUTCMES AND MEASURES: We provide a visual and descriptive
characterization of the network, used centrality measures to identify influential
patients, and ERGM to assess homophily and differential homophily.
RESULTS: The mean age of patients included in the analysis was 51 years; 53%
were female; 57% took oxycodone, 34% took hydrocodone and 9% took
buprenorphine/naloxone. On average, 53% of patients received less than 50 morphine
milligram equivalents (MME) daily, and the mean (standard deviation [SD]) number
of opioid prescriptions per patient was 14.4 (6.6). Sixty-four percent of patients had
commercial insurance, 28% had Medicaid, 5% had Medicare, and almost 2.5% used
cash payment only. All three centrality measures were in agreement on the
identification of the most influential patient in the opioid prescription network but
overall correlation between the measures was low. After controlling for the main
effects in the ERGM model, homophily was associated with age group, method of
payment, number and type of opioid prescription filled, mean daily MME, and number
of providers seen.
CONSLUSIONS: Characteristics of patients in an opioid prescription network may
influence which provider they choose and which patients they are connect to through
provider sharing. Interventions targeted at influential patients in the network may have
potential to influence social norms around the use and misuse of prescription opioids
that may lead to reductions in prescription opioid-related overdose deaths.
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KEY POINTS
Questions: What patient characteristics explain the pattern of shared-provider
connections among patients in an opioid prescription network and can we identify
influential patients as potential targets for opioid misuse prevention interventions?
Findings: In this social network analysis of PDMP data, we found extensive
homophily that was associated with age group, method of payment, number and type
of opioid prescription filled, mean daily dose, and number of prescribers ordering
opioid prescriptions. All three commonly used centrality measures identified the same
individual as the most influential patient in the network.
Meaning: Some patients in an opioid prescription network occupy influential
positions through a large number of shared providers or by virtue of their location on
paths between other patients in the network. Patients with similar characteristics tend
to share providers with each other. These findings suggest that interventions targeted
at influential, well-connected patients in the network may alter social norms around
prescription opioid use and misuse in a community.
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INTRODUCTION
The United States is experiencing an unprecedented prescription opioid overdose
crisis driven in part by few patients who possibly engage in doctor shopping which
may be identified in this context as patients obtaining opioid prescriptions from
multiple providers without the prescribers’ knowledge of other opioid prescriptions.1-3
Prescribers may be sought by patients using opioids because of their reputation around
opioid prescribing patterns such as use of high daily dose, use of combination opioids,
and frequent refills. Knowledge about individual prescriber clinical practices and
preferences may be shared among patients during co-visitation or social encounters in
the community. A recent study demonstrated that health care providers tended to share
patients with providers who have similar patients in their practice.4 This suggests that
patients prescribed opioids in a single state could be conceptualized as a network of
patients with connections through shared providers which we define in an opioid
prescription network. We hypothesized that patients within an opioid prescription
network may exert influence on each other’s opioid prescription utilization, including
opioid misuse as a result of living in the same community or sharing a common opioid
prescriber in the network, thereby impacting their network member’s opioid
prescription utilization and social norms around opioid use and misuse.5
Limited data suggests that a few high-intensity prescribers play a central role
in sustaining the prescription opioid epidemic.6,7 The pattern of provider-sharing may
help identify corresponding influential or central patients in a network, thereby
providing a clearer picture of where doctor shopping for prescription opioids may be
occurring. This understanding can inform the implementation of targeted interventions
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designed to improve prescription opioid utilization, prevent misuse, and treat opioid
use disorder among patients in a network. A network-based perspective has been used
to study a wide range of relational processes involving the flow of information
between network members connected to each other in a social network. This
perspective provides a framework that can be used to understand the structure of a
network and how it influences the behavior of individual members in the network.8-10
Landon et al. recently used network-based methods to demonstrate that characteristics
of patient-sharing networks and the position of providers in the network are associated
with healthcare resource utilization and cost.11 Another study used network analysis to
show racial differences in referral patterns for total hip replacement between
communities with low and high concentrations of back residents.12 Similar studies
have not been done using an opioid prescription network.
There is a dearth of knowledge about characteristics of patients possibly
engaged in doctor shopping for opioid prescriptions and methods to identify
prescription opioid doctor shopping behavior are limited. To the best of our
knowledge, network analysis has not yet been used to study an opioid prescription
network within any state. The purpose of this study was to explore and characterize a
patient-based opioid prescription network using social network analysis (SNA)
methods. Specifically, we described patterns of relationships between patients within
an opioid network, identified patients who have an influential role in the network, and
examined patient characteristics that may explain the observed pattern of providersharing relationships. We used the exponential random graph model (ERGM)
assuming conditional dyadic independence to examine the influence of some
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characteristics of individual patients in the network on their likelihood to form
network connections through provider sharing.
BACKGROUND
Over the past three decades opioid prescribing has increased tremendously in the
United States, with a corresponding rise in opioid misuse and opioid overdose-related
deaths.13,14 An important feature of this opioid epidemic is the association between
increasing rates of opioid prescribing and opioid-related morbidity and mortality.15-17
Among people who died of opioid overdoses, up to 66% used prescription opioid
analgesics originally prescribed for someone else; with doctor shopping being an
important means for acquiring these prescription opioids for misuse.18-24 In one study
designed to determine the prevalence of doctor shopping for different controlled
substances, prescription opioid medications (12.8%) were the most frequently
involved, followed by benzodiazepines (2.4%), and stimulants (1.4%).25 A crosssectional study of French patients on buprenorphine maintenance treatment identified
opioid misuse as a significant problem.3 Similar findings were reported in a review of
buprenorphine misuse.26 Doctor shopping for prescription opioid medications often
precedes fatal overdose, and accounts for about 40% of opioid-related overdoses, and
up to 30% of deaths.18,27-30 According to data from the Rhode Island Department of
Health, overdose deaths increased by more than 90% between 2011 and 2016. There
were 426 overdose deaths, of which 32% were related to fentanyl products, about 70%
were males, and 25% were in their 50s.31
In response to the epidemic of opioid misuse, state-run Prescription Drug
Monitoring Programs (PDMPs) were implemented in 49 states. These electronic
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databases collect information on controlled substance prescriptions including opioid
prescriptions, regardless of the sources of payment. These databases have been used
by prescribers and others to examine filling patterns consistent with prescription
opioid shopping behavior and potential misuse.32-34 The number of providers involved
in the care of a patient is often considered to be one of the strongest predictors of
potential opioid misuse because until recently providers often did not have ready
access to complete and accurate medication history at time of opioid prescribing.35-41
The use of the number of prescribers to fill controlled substances, referred to as
multiple prescriber episodes (MPE), has frequently been used as an indicator of doctor
shopping in PDMP databases. The absence of a universally accepted definition for a
threshold has led to wide variations in national estimates of doctor shopping, and
associated difficulties in making comparisons across different settings to evaluate the
effectiveness of interventions to prevent or reduce prescription opioid doctor shopping
behavior.18,32,34,42 We sought to evaluate the influence of MPE, number of opioid
prescriptions, number of pharmacies used, method of payment, age group, and gender
on the likelihood to form network connections through provider sharing.
Standard statistical approaches often assume independence of patients and/or
providers and ignore contextual relationships between providers and patients, and
among patients due geographic proximity, social influence, and local medical practice
norms; thereby, limiting our ability to evaluate prescription opioid doctor shopping
behavior. The goal of this study was to incorporate relational information using SNA.
These findings will better inform future intervention policies designed to improve
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social norms around prescription opioid use and prevent potential misuse among
patients within a community of patients using prescription opioids.
METHODS
Data source: We conducted a cross-sectional network-based study using the Rhode
Island (RI) PDMP data for the 2015 calendar year when the opioid crisis was a major
statewide concern to patients, prescribers and public health regulators. The 2015 data
contains records of schedule II to IV controlled substances dispensed by all retail
pharmacies in the state. It includes de-identified unique patient, prescriber, and
dispensing pharmacy information, and a limited number of variables such as age (in
years) and sex of the patient, National Drug Code (NDC), product name, strength,
formulation, and therapeutic class code of the drug plus number of days’ supply,
metric quantity dispensed, method of payment, and the date each prescription was
filled. Daily morphine milligrams equivalents (MME) were estimated using standard
conversion factors published by the Center for Disease Control and Prevention.
Cohort selection: A total of 2,058,816 controlled substance prescriptions were
dispensed

in

RI

in

2015

including

opioid

analgesics,

benzodiazepines,

psychostimulants, skeletal muscle relaxants, and sleep aids.43 Unique NDC codes were
used to identify 809,195 schedules II-IV opioid prescriptions filled at retail
pharmacies by 222,513 patients (Figure 1). To minimize the impact of less clinically
relevant network connections, we excluded institutional providers and prescribers who
issued opioid prescriptions to ≤ 6 patients during the study year. An institutional
provider was defined as any prescriber who had more than 2,400 patients on opioid
prescriptions

medications

per

year

attributed

9

to

their

Drug

Enforcement

Administration (DEA) number. Institutional DEA numbers are used by medical
students and residents to prescribe controlled substances under the supervision of a
licensed attending physician. Patients were required to have used only one type of
opioid medication and one source of payment method during the study period in order
to capture patients who were more likely on a stable pain management regimen and to
facilitate meaningful interpretation of the impact of these patient attributes. We limited
our analysis to commonly used and misused types of opioid medications (i.e.,
oxycodone and hydrocodone), and buprenorphine/naloxone that is used to treat opioid
use disorders. We hypothesized that patients on buprenorphine/naloxone for opioid
use disorders would connect to one another more often than expected by chance. In
addition, we restricted our analysis to patients who saw ≥ 3 prescribers for the same
opioid prescription and filled their opioid prescriptions at ≥ 3 pharmacies within one
year in order to capture patients with meaningful involvement in the patient-based
opioid prescription network. Multiple visits allow the network to capture relationships
between patients using opioid prescriptions. Several studies have used higher
thresholds of 4 or 5 to flag doctor/pharmacy shopping behavior when applied to
multiple types of opioid prescription per patient.42,44 We evaluated the influence of age
or age category, sex, source of payment, and type of opioid medication, number of
opioid prescriptions, average daily MME, number of providers, and number of
pharmacies on the likelihood of having a network connection defined by having one or
more shared providers in an opioid prescription network.
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Network-based framework
A network may be defined as a collection of points (i.e., vertices, nodes) and lines
(i.e., edges, ties, links, connections) joining them. In a social network, these vertices
represent people or groups of people and edges represent a kind of interaction between
them. PDMP data links each patient who received at least one opioid prescription to
one or more providers who ordered the opioid prescription(s). The receipt of one or
more opioid prescriptions from a prescriber was used as a proxy for a relationship or
interaction between a patient and a provider because state regulation requires a
physician visit for a written opioid prescription. These prescription records were used
to create an edge list, a two-column table, mapping patients to providers, each row
representing an individual opioid prescription. The edge list was used to create a
bipartite (two-mode) network where all pairs of patients and providers are joined by
an edge. The bipartite network was represented as a provider-by-patient incidence
matrix with cell entries indicating whether a provider wrote an opioid prescription to a
particular patient (Figure 2). The rows of the matrix consisted of individual patients
and columns identified providers. Pre-multiplying the bipartite incidence matrix by its
transpose gave a symmetric unipartite (one-mode) adjacency matrix with either
providers or patients only. The diagonal elements of the unipartite square matrix
corresponded to the number of providers who wrote at least one opioid prescription to
a given patient while the off-diagonal elements indicate the number of providers any
two patients had in common. This analysis focused on the patient-based network
where all nodes are represented by patients and connections (or edges) correspond to
shared-provider relationships. To avoid the creation of loops and multi-edges,
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diagonal elements were set to zero and off-diagonal elements with values greater than
one were set to 1, respectively. The construction of a simple patient-based network
graph is illustrated in Figure 3.
Network visualization: Network visualizations were selected to optimally place
nodes in positions that visually convey important information in the network, such as
the overall structure, location of influential patients in the network, and the presence of
distinctive subgroups (or clusters within the network).45,46 Some patient characteristics
were incorporated into visualizations using different node colors. Graphical
representation was used to examine degree, triangles, dyad-wise shared partners
(DSP), and edgewise shared partners (ESP) distributions to explore the network in
order to understand its structures. A DSP is a linked or unlinked dyad (i.e., patient
pair) where both patients are linked to a third network member. ESP is a linked dyad
in which both patients of the dyad are linked to a third network member. The
distribution of ESP in a network was used to show how many dyads had one shared
partner, two shared partners, and so on. Similarly, the distribution of DSP was used to
show the number of dyads in the network with one shared partner, two shared
partners, and so on. Node degree and triangles are defined below.
Network description: We evaluated the network with basic description of the
network size, density, and number of components, diameter, clustering, centrality and
modularity. The network size is defined as the number of nodes (i.e., patients) in the
network and its density is defined as the proportion of observed connections in the
network to the maximum number of possible connections in a randomly-generated
network of the same size. A path is a series of steps required to go from patient A to
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patient B. The shortest path is called the geodesic (distance) and the longest path is its
diameter. A component is a subgroup of patients in the network such that there is a
path connecting any two patients in the component directly or indirectly. A network is
said to be connected if all pairs of nodes are connected directly or indirectly. When the
largest connected component (LCC) is much bigger than the other components in a
network it is called the giant component. The LCC was used to improve visualization,
apply centrality measures, and develop ERGM models.
Global clustering measures the tendency of a network to form closed triangles
(i.e., connections between three patients). A triangle closes when three patients share
an opioid prescriber. Transitivity or clustering coefficient is the proportion of paths of
length two that are closed. For each patient, it refers to the ratio of the total number of
connections that exist among neighbors of the patient in the network to the total
number of possible connections that could exist if they were completely connected.47
This local clustering coefficient describes the extent to which network neighbors of a
particular patient are directly connected to each other and may be interpreted as the
probability that any two randomly selected neighbors of a particular patient in the
network are connected to each other. Lower local clustering coefficients indicate
fewer structural holes in the network and greater patient centrality.47,48
Network measures of centrality attempt to determine which patients are the
most influential or central persons in a network.47 The influence of an individual
patient on others in a network through dissemination of information may influence
social norms around opioid misuse and the sharing of opioid prescriptions in the
network. In general, we expect patients with more connections to exert greater
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influence on others in the network by sharing their attitudes towards opioid
prescription use with a wider group of patients. We employed three commonly used
centrality measures: degree, closeness, and betweenness centralities. Firstly, a
patient’s degree centrality is the number of other patients with direct connections to
the patient or simply the number of shared providers. Secondly, closeness centrality
measures how close a patient is to every other patient in the network, and reflects how
fast information and influence of a particular patient can disseminate to other patients
in the network. Formally, it is the inverse of the sum of all distances between patient
and all other patients in the network. Thirdly, betweenness centrality measures the
extent to which a patient acts as a bridge between pairs of other patients in the network
to facilitate the flow of information through the network. This implies that patients
with larger betweenness centralities are more likely to have contacts with many other
patients and may have greater influence regarding social norms around the use and
potential misuse of prescription opioids in the network.49,50 To estimate this measure,
we used a commonly applied algorithm proposed by Freeman.51 The most influential
patient in the network was identified using each centrality measure and a subgraph
corresponding to that individual and his or her immediate neighborhood was
constructed.52
The LCC was used to calculate centrality measures that were standardized for
comparison. Degree and closeness centralities were standardized dividing the estimate
and

by their maximum possible values,

, respectively, while the

betweenness was normalized by dividing through the number of pairs of vertices not
including the index vertex,

. A chi-squared test was used to
14

compare the distribution of patient attributes across tertiles of the standardized
centrality measures in the LCC. Assuming standardized centrality measures are
independent and identically distributed across patients, three separate multivariable
logistic regression models were fit to predict membership in the highest tertile of the
standardized centrality measure. We used Pearson’s correlation coefficient and 28
(10%) patients with the highest values for each standardized centrality measure to
assess the level of agreement in identifying the most influential patients.
Modularity, a chance-corrected statistic, is defined as the proportion of
connections that fall within observed groups based on patient characteristics minus the
expected proportion if the connections were randomly distributed. The scores ranges
from

to

and the closer the score value is to 1, the more the network exhibits

clustering with respect to the grouping factor. Modularity scores were used to examine
the influence of patient characteristics on patterns of connections in the opioid
prescription network. Furthermore, because network visualization and modularity
showed some evidence of clustering, mixing matrices and Pearson’s correlation were
examined. Mixing matrices were used to examine the number of connected dyads for
each possible combination of levels of categorical patient characteristic. These
exploratory analyses identified patient characteristics that were included in the ERGM.
Statistical network modeling: ERGMs were used to estimate the influence of
covariates on the likelihood of ties in the opioid prescription network. This class of
models formulates the probability of observing a set of network edges (and non-edges)
as:
,
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where,

is the random set of relationships (edges and non-edges) in a network,

the observed set of relationships,
network,
and

is

is a matrix of attributes for the vertices in that

is a vector of the network statistics,

is the vector of coefficients,

is a normalizing constant. Alternatively, the model states that the log odds

for any given edge to exist conditional on the remaining network connections, and can
be written as:
,
where,

is an indicator for a connection between pairs of patients in Y, and
is the change in

value as

is toggled from 0 to 1 (See

Technical Appendix for details).
We first modeled a simple random graph (i.e., null model) which contained
only an edges term to capture the network density.53 A simulated network of the same
size and density as the observed opioid prescription network was compared to the
observed network in order to identify important differences between the two networks.
The main effects and pairwise homophily interaction terms were added sequentially to
the null model to represent attributes of patients in the network. Homophily was
defined as the tendency for patients to connect with others like themselves. To
examine the influence of node attributes on the likelihood of having a shared provider
in the network, patient attributes were added to the model as main effects. We
hypothesized that specific patient attributes, including number of opioid prescriptions,
sex, age group, type of insurance coverage, type of opioid prescription, number of
prescribers and pharmacies, explain the pattern of patient connections through
provider sharing.
16

Homophily or assortative mixing is a tendency of patients to associate with similar
patients, while disassortative mixing is the tendency to associate with dissimilar
patients. Two types of dyadic interaction terms were added to the main effects model
to assess assortative and disassortative mixing in the network leading to patterns of
homophily or heterophily, respectively. First, we assessed the likelihood of provider
sharing when both patients in a dyad had the same level of a categorical attribute. The
number of opioid prescriptions was added as a continuous attribute. We hypothesized
that two patients with a similar number of opioid prescriptions filled during the study
year were more likely to form a network connection based on having a shared
provider. Secondly, we assessed the likelihood of provider sharing when both patients
in a dyad had different levels (i.e., dissimilar) of a categorical attribute such as type of
opioid prescription (differential homophily).
We limited this analysis to ERGM models that assume dyadic independence of
network connections.54 This assumption specified that patients sharing a provider were
dependent but independent if they had no provider in common. The null and main
effects models with and without homophily and differential homophily terms were
compared using Log L and related measures of deviance (-2LogL), the Akaike
information criterion (AIC) and the Bayesian information criterion (BIC).55,56 All tests
of statistical significance were two-sided and performed at the 0.05 significance level.
Data manipulation was performed with SAS, version 9.4 (SAS Institute, Cary, NC)
and network analysis was implemented with R statistical software, version 3.2.3 (R
Core Team 2016). The study was approved by the Institutional Review Board at
University of Rhode Island.
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RESULTS
A total of 372 patients prescribed opioids by 746 providers during a one-year study
period met the inclusion criteria for meaningful involvement in the opioid prescription
network in RI. Table 1 presents a summary of the characteristics of all the patients
compared to those in the LCC. The mean (SD) age of all patients in the sample was 51
(14) years with 50% aged 45-64 years, and 53% were female. More than 5,000 opioid
prescriptions were filled, of which 57% were prescriptions for oxycodone, 34% were
for hydrocodone and 9% were for buprenorphine/naloxone. The mean number of
opioid prescriptions filled per patient was 14.4 (SD=6.6) with 53% receiving on
average less than 50 MME daily. However, 25% of patients had on average more than
90 MME per day. Most patients paid for all their opioid prescriptions with commercial
insurance and only 2.4% used cash payment exclusively. About half of the patients
filled opioid prescriptions written from ≥4 prescribers while 31% filled their opioid
prescriptions at ≥4 pharmacies during the one-year study period.
Network characteristics: The bipartite network had a total of 1,118 nodes (746
providers plus 372 patients) with 1,460 unique connections between them
corresponding to unique patient-provider relationships resulting from one or more
opioid prescriptions. There were more prescribers in the network than patients. The
overall bipartite density was only 0.5%. The full opioid network contained 372
patients with 1,980 connections among them; 32 (8.6%) had no shared providers
(isolates) [Figure 4]. The full network had 55 connected components including 32
isolates, and the LCC contained 74% of all the patients in the network including
95.66% of all connections; the second largest connected component consisted of only
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2.4% (Figure 5). The full network and its LCC demonstrated apparent clustering with
at least 4-5 large clusters. There was some evidence of clustering by age group, opioid
type, average daily dose, and method of payment; however, no pattern by gender was
apparent. The most obvious clustering is seen among patients who were on
buprenorphine/naloxone. One possible explanation for this clustering is that under the
Drug Addiction Treatment Act (DATA) of 2000, only certain qualified providers are
authorized to prescribe buprenorphine/naloxone as medication-assisted treatment for
people diagnosed with an opioid use disorder.
Characteristics of the full opioid network and its LCC are presented in Table 2.
The LCC had an overall density of 5% compared with 3% for the whole network. The
average number of shared providers was higher among those in the LCC (13.8)
compared to the whole network (10.6). The average path length and longest path were
the same (≈ 10) suggesting that the rate of flow of information diffusion in the LCC
would be similar to that of the full network. However, the density around the most
central patient was 65%, average number of shared providers was 25 (SD=9) and the
average path length only 1.4 (Figure 6). Assortative mixing and the fraction of
transitive triples (transitivity) were higher for the whole cohort. About 85% of patients
who shared a provider were connected to other patients who also shared a provider
with each of them. Seventy-five of patients were connected to one or more patients
with at least one similar characteristic.
The number of shared providers was quite heterogeneous across patients
(Figure 7). While there are many patients with few shared providers, there was a nontrivial number with many shared providers. In particular, there are 28 patients with 29
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shared prescribers. This may correspond to providers in the same practice or on-call
group. Given the nature of the decay in the degree distribution, a log-log scale was
used to assess the results. The middle panel in Figure 7 shows a somewhat linear
decay in the log-frequency as a function of the log-degree. A plot of the average
neighbor degree versus vertex degree suggests that while there is a tendency for
patients with many shared providers to connect to each other, those with fewer shared
providers tend to connect with both patients having lower and higher number of shared
providers (assortative degree network). This is illustrated by the high network density
around the most influential patient (Figure 6).
Centrality measures: Overall, there was moderate correlation between degree and
closeness (r = 0.53; p < 0.001), and between closeness and betweenness(r = 0.48; p <
0.001) centralities. However, correlation between degree and betweenness centralities
was low (r = 0.19; p=0.002).

Among 56 patients with the highest standardized

centrality values for any of the three measures, 14 (25%) were identified by degree
and closeness centralities, 12 (21%) by closeness and betweenness centralities, 7
(12%) by degree and betweenness centralities, and only 5 (8.93%) by all three
measures. However, all three measures identified the same patient as the most
influential patient in the network; a 48-year-old female on Medicare taking
Oxycodone who filled 19 prescriptions for an average daily MME > 90 and saw 5
different providers and visited 5 different pharmacies during one calendar year (data
not shown).
Tertiles of standardized centrality measures estimated from the LCC are
presented in Table 3. Age group, type of opioid used, average daily dose, and number
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of opioid prescribers were associated with at least one standardized centrality measure
while gender, method of payment, and number of pharmacies were not associated with
any centrality measure. Based on multivariable logistic regression model, age group,
type of opioid used, average daily dose, and number of opioid prescribers were
associated with the highest tertile of at least one standardized centrality measure, after
adjusting for other covariates in the model (Table 4). Patients aged 45-64 years were
most likely to be classified as having the highest levels of standardized degree
centrality tertile as compared to those ages 65 years and older. Furthermore, patients
who took on average > 90 daily MME were 6.7 times more likely to have the highest
standardized degree centrality tertile compared to those on < 50 MME per day. This
suggests that patients on higher daily doses of opioids tend to have more shared
providers. Based on standardized closeness and betweenness centralities, patients who
had ≥ 4 providers were more likely to be classified in the highest tertile of their
respective standardized centrality measures. As compared with patients on
hydrocodone, patients on buprenorphine/naloxone were less likely to be in the highest
standardized degree centrality tertile and more likely to be in the highest standardized
betweenness centrality tertile. This suggests that patients with few connections may be
crucial for the diffusion of information and prescription opioids in the network.
Network connectivity: Graphical examination of triangles, degree, DSP, and ESP were
used to understand the network structure (Figure 8). The observed LCC of the network
had many more completed triples than a randomly-generated network of the same size
and density. Similarly, the LCC had many patients with few shared providers (lowdegree nodes) and few patients with many shared providers (high-degree nodes)
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compared with a random network of the same size and density. Edgewise and dyadwise shared partner distributions also differed in the observed LCC and random
networks with the observed LCC having more patients with multiple ESP and DSP
compared with the random network, which indicated a large number of patients with
one or two shared partners, and hardly any higher level multiples.
Mixing matrices is presented in Table 5. Provider sharing tended to be between
two patients who are both female, one younger and the other middle-aged, both on
commercial insurance, both on oxycodone, one on low-dose and the other on
intermediate daily dose, or both with 4 or more opioid prescribers. For example, of
825 connected pairs of patients who took hydrocodone in opioid type mixing matrix,
659 (80%) are connected to a patient who took only hydrocodone. This suggested a
higher likelihood of patients who took hydrocodone to share providers with other
patients who also took hydrocodone (i.e., homophily of opioid prescribing). From
Table 6 opioid type, number of providers, average daily MME and age group had the
highest modularity score and may explain some of the clustering observed in the
network. From the perspective of the network connections and patient attributes, the
GC was a reasonable representation of the full opioid prescription network.
Results from ERGMs: Based on a null model with only the edge term to account for
the number of connections in the network, the probability of a connection between any
randomly selected two patients was 0.06 (i.e., density of the network). This baseline
model was compared to models with more constraints. Although the null model
provided a reasonable representation of the observed network density, it failed to
represent other features of the network such as transitivity. A plot of 1,000 simulated
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networks of the same size and density as the null model was used to assess how well
the null model captured transitivity. The point on the x-axis in Figure 9 corresponds to
the location of 12,514 triangles in the observed patient network, which was much
higher than the number of triangles in any of the 1,000 simulated networks. This
suggested that a more complex model with constraints on the number of triangle was
needed to capture transitivity and other network characteristics in the observed opioid
prescription network.
Model with main effects of patient attributes: Based the modularity score and clinical
importance, we selected gender, age category, payment method, opioid type, number
of prescriptions, average daily dose in MME, number of provider who wrote opioid
prescriptions to the patient in one calendar year (categorical) and number of
pharmacies visited during the year to fill opioid prescriptions (categorical) to include
in the main effects model. The null hypothesis was that there was no association
between each patient attribute and the likelihood of a patient having a connection
through provider sharing, after controlling for all other attributes in the model. The
results of the main effects model are summarized in Table 7. Positive coefficients (i.e.,
log odds of a connection) indicate a higher likelihood of sharing a provider with
another patient in the network (compared to the reference level for categorical
attributes) and negative coefficients indicate lower likelihood. The total number of
opioid prescription filled was positively associated with an increased likelihood of
having a shared provider. Male patients were less likely to have a shared provider in
the network than female patients, although this difference was not statistically
significant. Unlike patients on Medicare, patients who used Medicaid or cash
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payments exclusively were less likely to have a shared provider with other patients in
the opioid prescription network than patients who used commercial insurance but the
difference was not statistically significant for the use of cash term. With only 9
patients who used cash exclusively, there may not have been enough power to detect
any difference. Patients who took either hydrocodone or oxycodone were more likely
to have a shared provider in the network. A higher average daily dose of opioids was
associated with a greater the chance of having a shared provider in the network.
Furthermore, patients who had ≥ 4 opioid prescribers in one year were more likely to
have at least one shared provider in the opioid prescription network than those with
fewer providers. However, patients who filled their opioid prescriptions at ≥ 4
pharmacies were less likely to have a shared provider in the network than those who
used fewer pharmacies. These results are consistent with our results of network
visualizations, mixing matrices, Pearson’s correlation coefficients and modularity
scores.
Model with main effects and homophily terms: We hypothesized that two patients with
the same level of a categorical attribute, or similar number of opioid prescriptions
filled during the study year, were equally likely to form a network connection based
on having a shared provider. The results of the model with main effects and
homophily terms are summarized in Table 8. Positive and significant parameter
estimates for gender, age category, opioid type, average daily MME, and number of
providers all indicated the presence of homophily effects for these patient attributes,
after controlling for their main effects in the model. All homophily interaction terms
were statistically significant at 0.05 level except for method of payment that was only
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significant at 0.10 significance level. Use of ≥ 4 pharmacies had no homophilic
effects. For the number of opioid prescriptions filled during the year, a negative
coefficient indicated homophily because the absolute difference in size decreases as
the sizes of both values in a dyad becomes more identical. The addition of homophilic
terms did not alter the qualitative associations of the main attributes.
Model with main effects and differential homophily terms: The results of the model
with differential homophily terms are presented in Table 9. Overall homophilic effects
of gender were seen mainly among females; for age mainly among patients 65 years
and

older;

for

opioid

type

among

all

levels

especially

those

on

buprenorphine/naloxone subgroup; and for number of providers mainly among those
who saw ≤ 4 providers in a year, after controlling for other variables in the model,
respectively. Overall homophily effects of payment type were significant at the 0.10
level only among those on commercial insurance and there were no homophilic effects
within other subgroups of payment method. Adjusted homophily effects of opioid
dose and number of pharmacies did not achieve statistical significance. The addition
of homophily terms did not alter the qualitative association of the main attributes,
except for the subgroup of patients aged 65 and older. The model with main effects
and differential homophily terms had a lower AIC than the baseline model and the
model with main effects and homophilic terms.
DISCUSSION
This study suggests that patients in an opioid prescription network were highly
connected. Our sample of 372 patients had 1,980 shared-provider connections and
almost 75% of patients were connected to each other either directly or indirectly in
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one giant component that consisted of 96% of all connections in the full network. The
intensity of prescription opioid use and possible misuse is reflected in the number of
prescribers in the network. There were twice as many providers as patients using
prescription opioids. More than half the patients saw at least four providers although
they appeared to be on a stable opioid regimen. A majority of patients were female
and aged 45-64 years old. The underlying structure of the network was significantly
different from that of a randomly-generated network of the same size and density. The
random network was never designed as a model for observed networks because it
ignores node attributes that may explain observed clustering. The distribution of the
number of shared providers was bimodal with a second peak corresponding to 29
shared prescribers. This may represent a group of patients who belong to a large
medical group with many providers who cater for all the patients, including pain
management.
Our opioid prescription network demonstrated homophily by opioid type,
opioid dose, age group, sources of payment and number of providers. The most
obvious

clustering

on

visualization

was

seen

among

patients

on

buprenorphine/naloxone. One possible explanation for this clustering is that under the
Drug Addiction Treatment Act (DATA) of 2000, only certain qualified providers are
authorized to prescribe buprenorphine/naloxone as medication-assisted treatment for
people diagnosed with an opioid use disorder. Such patients are more likely to seek
certified providers in the network. Overall, 75% of patients were connected to one or
more patients with at least one similar characteristic. Furthermore, patients with many
shared providers were more likely to connect to each other and such patients may have
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patterns of use consistent with potential abuse. Although older patients with more
medical conditions tend to be on opioid therapy, they had fewer shared providers
compared to younger patients. This may be due older patients having a stable health
insurance and an established primary care provider who meets their medical needs.
Centrality measures suggested that relatively few patients were at the center of the
opioid prescription network. Similar conclusions have been drawn about providers
using standard statistical methods.6,7 The level of connectedness was captured by
degree and closeness centrality measures, which identified higher daily opioid dose to
be associated with the number of shared providers (i.e., degree centrality) and
closeness centrality, which is a measure of how quickly information emanating from
one patient in the network could spread to other patients assuming each shared
provider relationship offers ample opportunities to disseminate information and
training on opioid misuse prevention.
If network connections represent the flow of information and influence, then a
measure of how often a patient in the network acts as a bridge between other patients
may provide a more useful measure. Betweenness centrality assumes there is flow of
information in a network and attempts to capture the influence of each member over
the spread of that information. However, in calculating this measure it is assumed that
all patients in the network have the same probability of sharing information received
and that the information spreads around via the shortest paths. This suggests that more
information would pass through patients with larger betweenness centralities whose
removal from the network could disrupt the network cohesion. In practice, patients
may not spread information at the same rate and information may not spread through
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the shortest paths.47 Despite these limitations, betweenness centrality remains a very
useful guide to the potential influence a network member over the flow of information
and may serve as a useful way to identify patients for prevention and treatment
interventions. It also has a wide range of values making it easier to distinguish
between central and less central patient targets. Our analysis suggested that such
intervention would seek patients with MPE or those on opioid use disorder treatment
first. These findings support the use of multiple provider episodes as an indicator of
potential opioid misuse.44,57,58 Additional studies are needed to evaluate the practical
advantages of using betweenness centrality with or without MPE. This can be easily
implemented through sequential analysis of PDMP data which were instituted or
strengthened primarily in response to the prescription opioid epidemic.
Our results suggest that patients on prescription opioid medications are not
isolated from their social environment, but rather are connected to each other via
provider sharing. Sharing an opioid prescriber may increase the probability of
establishing a personal relationship with another patient on opioid therapy through a
chance encounter in a physician office or the community because, unlike some other
controlled substances, oxycodone, hydrocodone and buprenorphine/naloxone require
an office visit for a written prescription. These relationships form a basis for
constructing an opioid prescription network using comprehensive and reliable
prescription information captured by the PDMP at the state-level irrespective of the
payer. New state regulations and laws mandates quantity limits on opioid
prescriptions. For patients requiring chronic opioid therapy, this may lead to biweekly
or monthly office visits for opioid prescription renewals. Refills may be provided by a
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partner in the same practice or a provider on-call. After office hours, the patient may
visit the emergency room or a walk-in clinic for a short supply. Broadly defined,
doctor shopping involves visiting many providers during an episode of illness, or to
acquire controlled substances illicitly. In the context of acquiring prescription opioid
medications for potential misuse, patients may engage in doctor shopping because of
long waiting times for an appointment, inconvenient office hours, persistence of
painful condition, provider attitude, or absence because of vacation.59-61 Hence, doctor
shopping behavior may be a reflection of fragmented care in a patient with persistent
pain. We had no clinical diagnosis information, place of service, geographic location,
or provider specialty to impugn any diagnosis or clinical condition for opioid
prescriptions.
A recent social network analysis of physicians in the United States showed that
providers tend to be connected to other providers with similar patients in a patientsharing network.5 Our study shows substantial clustering and assortative mixing
driven by patient characteristics. The extent of homophily is similar to what has been
observed in other social settings.62,63 The cross-sectional nature of our study does not
allow us infer the reasons for preferential connections of patients using prescription
opioid to other patients with similar characteristics. One implication of homophily is
that it could facilitate the spread of valuable health information through targeted
training of influential patients in the network and reduce the diffusion of risky
behavior around prescription opioid use and misuse.
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The successful application of network science to a systematic problem such as
the opioid crisis requires careful consideration of the choice of nodes and the
connections between them to ensure clinical significance. This study demonstrates
several advantages of using PDMP to identify connections within a network of
patients on prescription opioid therapy. The sample for this analysis was derived from
a statewide PDMP data which provided a unique opportunity to identify virtually all
provider-sharing relationships among patients on prescription opioids regardless of the
sources of payment. Because the data is collected for use in clinical decision-making
at the point of patient care, it is assumed to be accurate and comprehensive. It provides
data that can be used to identify patterns of opioid prescription filling that raise
concerns for potential opioid misuse.
LIMITATIONS
These analyses are subject to a few limitations. First, the sharing of an opioid
prescriber was used to infer an information sharing relationship between patients on
prescription opioids. Patterns of provider sharing may be a reflection of fragmented
care rather than doctor shopping of prescription opioids for illicit use. We cannot
identify doctor shopping from prescription data because in this context doctor
shopping often involves an illegal and covert activity. PDMP data do not reveal the
reasons why patients obtained multiple prescriptions from so many different
prescribers. Second, we excluded providers with very few patients or potential
institutional providers. We have no evidence that all prescribers were licensed in the
state for the whole calendar year and such providers may have fewer patients. Their
removal may cause network fragmentation, fundamentally altering some of the
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properties of the network. Third, we used a threshold of 2,400 for so-called
institutional providers but there could have been other institutional prescribers with
fewer patients similar to non-institutional providers. Furthermore, providers in single
group practice are more likely to see the same patients creating a false pattern of
doctor shopping behavior. Because our analysis did not account for the grouping of
physician practices, there is potential for misclassification of the number of providers
seen. Moreover, our analysis failed to capture evidence of geographic proximity, covisitation to providers, or community social interactions. Fourth, our data was limited
to a single calendar year for one state with very few variables making it difficult to
characterize the nature of the relationships. We did not account for prescription opioid
fills across the state-lines. Indeed, PDMP data may underestimate the prevalence of
prescription opioid misuse because it focuses on prescribers and patients ignoring
other sources of illicit prescription opioid use, including theft, illicit drug use, and
unlicensed internet pharmacies. Fifth, the enforcement of regulations on electronic
filing of controlled substance fillings, merging of prescriber practices, entry and exit
of providers and pharmacies from the market may alter the patterns of relationships
substantially. Sixth, the usefulness of closeness centrality in observed networks is
often limited by the existence of several components because distance between two
patients in different components is considered infinite. In addition, the range of
closeness centrality values is relatively narrow, making it difficult to distinguish
between an influential and a less influential patient in the network for the purpose of
designing interventions. Seventh, the ERGM model of characteristics associated with
network connections, homophily and differential homophily assumes conditional
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independence of dyads, which is largely unrealistic in practice.64 ERGM models of
large networks perform poorly due time-consuming algorithms and non-converging
Markov chains, and associated model degeneracy. Furthermore, nodes are assumed
fixed and homogenous except for differences captured in available nodal attributes.
The use of a subnetwork in which these assumptions hold limits generalizability of
results because every network is unique due to inconsistency under sampling.
CONCLUSIONS
Patterns of provider sharing in a patient-based prescription opioid network, suggest
that patients prescribed opioids may have extensive connections with other that could
be leveraged to improve dissemination of health promotion or disruption of negative
behaviors with the use and misuse of opioid prescriptions. The characteristics of these
patients and the structure of the network uniting them influence their health choices.
The analysis suggests that opioid prescribers could easily be sought by patients who
doctor shop for prescription opioids. Interventions targeted at influential patients in the
network may have potential to influence social norm around the use and misuse of
prescription opioids eventually leading to reductions in opioid overdoses and opioid
use disorders.
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TABLES AND FIGURES

Table 1. Characteristics of Patients in an Opioid Prescription
Network of Patients in the RI PDMP in 2015 (n=372)
Characteristic
Number of providers
Number of pharmacies
Number of opioid Rx
Total daily MME, mg
Age (years)
Age group (years)
21-44
45-64
65+
Gender
Female
Male
Method of payment for opioids
Commercial
Medicare
Medicaid
Cash
Number of providers
3
4+
Number of pharmacies
3
4+
Type of opioid medication used
Buprenorphine/naloxone
Hydrocodone
Oxycodone
MME category, mg
< 50
50-90
>90

All (N=372)

LCC (N=274)

Mean (SD)
3.92 (1.27)
3.99 (1.34)
3.47 (0.82)
3.49 (0.85)
14.36 (6.56)
14.01 (5.52)
1,238 (1,958)
1262 (1976)
50.59 (13.84)
49.34 (13.45)
N (%)
126 (33.87)
189 (50.81)
57 (15.32)

103 (37.59)
134 (48.91)
37 (13.50)

197 (52.96)
175 (47.04)

139 (50.73)
135 (49.27)

239 (64.25)
104 (27.96)
20 (5.38)
9 (2.42)

178 (64.96)
5 (1.82)
15 (5.47)
76 (27.74)

187 (50.27)
185 (49.73)

134 (48.91)
140 (51.09)

257 (69.09)
115 (30.91)

187 (68.25)
87 (31.75)

33 (8.87)
126 (33.87)
213 (57.26)

32 (11.68)
93 (33.94)
149 (54.38)

197 (52.96)
81 (21.77)
94 (25.27)

136 (49.64)
67 (24.45)
71 (25.91)

Abbreviations: LCC= largest connected component; Rx=prescription(s)
SD=standard deviation; MME=morphine milligram equivalent
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Table 2. Summary of Characteristics of a Network of Patients and a
Network of Providers in the RI PDMP in 2015
Network characteristics
Basic characteristics
Number of vertices
Number of edges
Density
Average degree (SD)
Average path length
Diameter
Global transitivity
Mean Local transitivity
Assortative coefficient
Number of components
Size of LCC

Patient-based Network
All
LCC
372
274
1,980
1,894
0.0287
0.0506
10.7 (11.7)
13.8 (12.0)
4.18
4.19
10 (13)
10 (13)
0.853
0.852
0.731
0.718
0.785
0.751
55
1
274
274

Provider-based Network
All
LCC
746
479
1,901
1,437
0.0068
0.0126
5.1 (4.1)
6.0 (4.7)
5.05
5.10
11
11
0.498
0.460
0.839
0.789
0.156
0.040
55
1
479
479

Abbreviations: LCC= largest connected component; SD=standard deviation.
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Table 3. Distribution of standardized centrality measures by patient characteristics using the largest connected component
of the opioid prescription network
Quartiles of standardized centrality measures
Betweenness centrality
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Characteristic
Age group (years)
21-44
45-64
65+
Gender
Female
Male
Payment method
Commercial
Medicare
Medicaid
Cash
Number of providers
3
4+
Number of pharmacies
3
4+
Most commonly filled opioids
Bup/naloxone
Hydrocodone
Oxycodone
MME category, mg
< 50
50-90
>90

Degree centrality

T1
(n=91)

T2
(n=92)

T3
(n=91)

p-value

T1
(n=93)

T2
(n=89)

T3
(n=92)

36
36
19

28
55
9

39
43
9

0.022

36
41
16

35
38
16

32
55
5

45
46

51
41

43
48

0.518

51
42

45
44

54
29
6
2

61
24
5
2

63
23
4
1

0.883

61
25
5
2

58
33

42
50

34
57

0.001

62
29

69
23

56
35

3
36
52

12
31
49

49
20
22

43
26
23

Closeness centrality
T1
(n=92)

T2
(n=91)

T3
(n=91)

0.035

37
38
17

33
45
13

33
51
7

0.178

43
49

0.545

45
47

45
46

49
24

0.765

54
27
7
1

63
24
3
2

0.825

55
29
6
2

65
22
3
1

58
25
6
2

0.750

50
43

43
46

41
51

0.453

53
39

46
45

35
56

0.032

0.148

64
29

61
28

62
30

0.976

64
28

61
30

62
29

0.934

17
26
48

0.024

10
46
37

21
25
43

1
22
69

< 0.001

7
38
47

14
32
45

11
23
57

0.106

44
21
26

0.784

66
12
15

41
19
29

29
36
27

< 0.001

53
18
21

49
19
23

34
30
27

0.057

p-value

Abbreviations: MME=morphine milligram equivalent, Bup=Buprenorphine; T1-T3=Tertile 1, Tertile 2 & Tertile 3.

p-value

Table 4. Odds Ratios (95% CI) Associated with a Patient being Classified in the Upper Tertile of Standardized
Centrality Measures
Standardized betweenness centrality

Standardized degree centrality

Standardized closeness centrality

Characteristic
Unadjusted OR
Adjusted OR
Unadjusted OR
Adjusted OR
Unadjusted OR
Number of opioid Rx
0.96 (0.92, 1.01)
NS
1.10 (1.047, 1.155
NS
1.01 (0.96 1.05)
Age group (years)
65+
Ref.
NS
Ref.
Ref.
Ref.
21-44
1.90 (0.81, 4.43)
2.88 (1.03, 8.08)
4.27 (1.41, 12.86)
2.02 (0.80, 5.07)
45-64
1.47 (0.64, 3.38)
4.46 (1.63, 12.15)
5.12 (1.77, 14.83)
2.63 (1.08, 6.44)
Gender
Female
Ref.
NS
Ref.
NS
Ref.
Male
1.232 (0.744, 2.04)
1.27 (0.77, 2.10)
0.83 (0.50, 1.37)
Payment method
Cash
Ref.
NS
Ref
NS
Ref.
Commercial
2.19 (0.24, 20.03)
0.82 (0.13, 5.05)
0.73 (0.12, 4.46)
Medicare
1.46 (0.12, 17.23)
0.69 (0.11, 4.42)
0.74 (0.12, 4.69)
Medicaid
1.74 (0.18, 16.39)
0.38 (0.04, 3.36)
1.00 (0.13, 7.89)
# of providers
3
Ref.
Ref.
Ref.
NS
Ref.
4+
2.02 (1.21, 3.38)
2.62 (1.49, 4.59)
1.30 (0.79, 2.15)
1.89 (1.13, 3.15)
# of pharmacies
3
Ref.
NS
Ref.
NS
Ref.
4+
1.60 (0.93, 2.68)
1.06 (0.62, 1.82)
1.01 (0.59, 1.73)
Opioid type
Hydrocodone
Ref.
Ref
Ref.
Ref.
Ref.
Bup/naloxone 2.92 (1.28, 6.69)
4.18 (1.73, 10.07)
0.10 (0.01, 0.81)
0.02 (0.00, 0.16)
1.59 (0.67, 3.80)
Oxycodone
1.23 (0.69, 2.16)
1.13 (0.63, 2.02)
2.78 (1.56, 4.95)
1.10 (0.52, 2.33)
1.89 (1.06, 3.35)
MME category, mg
< 50
Ref.
NS
Ref.
Ref.
Ref.
50-90
0.96 (0.51, 1.79)
4.29 (2.28, 8.06)
4.18 (1.97, 8.84)
2.43 (1.31, 4.51)
>90
1.21 (0.66, 2.21)
2.26 (1.21, 4.26)
6.73 (2.69, 16.86)
1.84 (0.99, 3.41)
Abbreviations: CI=confidence interval; OR=odds ratio; Rx=prescription; MME=morphine milligram equivalent, Bup=Buprenorphine,
NS=not statistically significant

Adjusted OR
NS
NS

NS
NS

Ref.
2.09 (1.21, 3.64)
NS
NS

Ref.
2.32 (1.24, 4.34)
2.31 (1.20, 4.44)

Table 5. Mixing Matrices of Categorical Patient Attributes for an Opioid Prescription
Network of Patients
Patient Attributes
Gender

N (%)

All, N=372
Mixing matrix
1
2

3

a

4

N(%)

LCC, N=274
Mixing matrix
1
2

3

Female
197 (52.96)
496
949
139 (50.73)
479 904
Male
175 (47.04)
949
535
135 (49.27)
904 511
Age category
<44
126 (33.87)
263
745
119
103 (37.59)
262 723
111
45-64
189 (50.81)
745
635
192
134 (48.91)
723 606
170
65+
57 (15.32)
119
192
26
37 (13.50)
111 170
22
Use of cash
Cash only
9 (2.42)
1
73
5 (1.82)
1
69
Insurance only
33 (97.58)
73
1906
269 (98.18)
69
1824
Payment method
Commercial
239 (64.25)
887
95
791 52
178 (64.96)
855 92
664
Medicaid
20 (0.00)
95
3
60
2
15 (0.00)
92
2
57
Medicare
104 (27.96)
701
60
160 19
76 (27.74)
664 59
154
Cash
9 (2.42)
52
2
19
1
5 (1.82)
49
2
18
Type of opioid medication
Bup/Naloxone
33 (0.00)
88
14
76
32 (0.00)
88
14
76
Hydrocodone
126 (33.87)
14
158
687
93 (33.94)
14
152
659
Oxycodone
213 (57.26)
76
687
957
149 (54.38)
76
659
905
Daily MME
<50
197 (52.96)
339
471
370
136 (49.64)
301 457
347
50-90
81 (21.77)
491
231
336
67 (24.45)
457 231
329
>90
94 (25.27)
370
336
233
71 (25.91)
347 329
229
Number of prescribers
3
187 (50.27)
526
718
134 (48.91)
512 693
4+
185 (49.73)
718
736
140 (51.09)
689
Number of pharmacies
3
257 (69.09)
908
883
187 (68.25)
856 852
4+
115 (30.91)
883
189
87 (31.75)
852 186
Abbreviations: LCC= largest connected component; Bup=Buprenorphine; MME=morphine milligram equivalent,
a
Number of categories for each attribute

a

4

49
2
18
1

Table 6. Clustering by Node Attribute using Modularity Score
Node attributes
Total
LCC
Gender
0.021
0.023
Age group (years)
-0.012
0.025
Age, years (continuous)
0.024 -0.013
Payment method
0.013
0.015
Number of providers (continuous)
0.080
0.078
Number of providers (categorical)
0.132
0.130
Number of pharmacies (continuous)
-0.009 -0.009
Number of pharmacies (categorical)
-0.012 -0.012
Type of opioid prescription used
0.080
0.082
Number of opioid prescriptions
0.018
0.018
Total daily dose, MME (mg)
-0.006 -0.007
MME category, mg
0.068
0.066
Abbreviations: LCC= largest connected component; MME=morphine milligram equivalent.
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Table 7. Main Effects Model to Estimate the Log odds of a tie between two
patients in the Opioid Prescription Network of Patients Using the LCC
Term
Edges
Number of opioid prescriptions
Gender
Female
Male
Age category
<44
45-64
65+
Payment method
Commercial
Medicaid
Medicare
Cash
Opioid type
Buprenorphine/Naloxone
Hydrocodone
Oxycodone
Daily MME
<50
50-90
>90
Number of prescribers
3
4+
Number of pharmacies
3
4+

Estimate
-5.661
0.009

SE
0.174
0.003

P-value
< 0.001
0.004

Ref.
-0.002

0.035

0.953

Ref.
0.064
-0.620

0.038
0.074

0.091
< 0.001

Ref.
-0.468
0.132
-0.201

0.086
0.045
0.127

< 0.001
0.003
0.115

Ref.
0.875
0.983

0.092
0.080

< 0.001
< 0.001

Ref.
0.533
0.703

0.048
0.060

< 0.001
< 0.001

Ref.
0.133

0.036

< 0.001

Ref.
-0.040

0.037

0.284

Abbreviations: SE=standard error; MME=morphine milligram equivalent;
AIC=Akaike information criterion; BIC=Bayesian information criterion,
LCC= largest connected component.
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Table 8. Main Effects Model with Homophily Terms to Estimate
the Log odds of a tie between two patients in the Opioid
Prescription Network of Patients Using the LCC
Term
Edges
Number of opioid prescriptions
Gender
Female
Male
Age category
<44
45-64
65+
Payment method
Commercial
Medicaid
Medicare
Cash
Type of opioid prescription
Buprenorphine/Naloxone
Hydrocodone
Oxycodone
Average daily MME, mg
<50
50-90
>90
Number of prescribers
3
4+
Number of pharmacies
3
4+
Homophily terms
Number of opioid prescriptions
Gender
Age category
Method of payment
Type of opioid prescription
Average daily MME, mg
Number of prescribers
Number of pharmacies

Estimate
-6.283
0.031

SE
0.191
0.004

P-value
< 0.001
< 0.001

Ref.
-0.011

0.034

0.746

Ref.
0.064
-0.637

0.039
0.076

0.845
< 0.001

Ref.
-0.431
0.178
-0.116

0.094
0.050
0.134

< 0.001
< 0.001
0.386

Ref.
0.786
0.776

0.091
0.081

< 0.001
< 0.001

Ref.
0.476
0.711

0.048
0.060

< 0.001
< 0.001

Ref.
0.094

0.033

0.005

Ref.
-0.066

0.043

0.130

-0.060
0.106
0.107
0.107
0.456
0.169
0.579
-0.062

0.006
0.048
0.053
0.060
0.059
0.052
0.050
0.056

< 0.001
0.027
0.016
0.074
< 0.001
0.001
< 0.001
0.265

Abbreviations: SE=standard error; MME=morphine milligram equivalent;
AIC=Akaike information criterion; BIC=Bayesian information criterion.
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Table 9. Main Effects Model with Differential Homophily Terms to Estimate the Log odds of a tie between
two patients in the Opioid Prescription Network of Patients Using the LCC
Term
Edges
Number of opioid prescriptions
Gender
Female
Male
Age category
<44
45-64
65+
Payment method
Commercial
Medicaid
Medicare
Cash
Type of opioid prescription
Buprenorphine/Naloxone
Hydrocodone
Oxycodone
Average daily MME, mg
<50
50-90
>90
Number of prescribers
3
4+
Number of pharmacies
3
4+
Abbreviations:

Estimate
-9.485
0.031

Main effects
SE
0.412
0.004

P-value
< 0.001
< 0.001

Ref.
0.094

Ref.
0.059

0.110

0.212
NA

0.097
NA

0.028
NA

Ref.
-0.071
-0.744

Ref.
0.126
0.096

0.576
< 0.001

-0.058
0.152
0.505

0.148
0.139
0.264

0.697
0.273
0.056

Ref.
-0.304
0.349
-0.031

Ref.
0.136
0.151
0.164

0.025
0.021
0.852

0.263
-0.480
-0.152
0.774

0.159
0.740
0.179
1.097

0.098
0.516
0.397
0.480

Ref.
1.760
2.661

Ref.
0.138
0.276

< 0.001
< 0.001

4.776
0.919
-0.719

0.327
0.315
0.300

< 0.001
0.004
0.016

Ref.
0.447
0.725

Ref.
0.088
0.088

< 0.001
< 0.001

0.083
0.151
0.028

0.118
0.118
0.130

0.480
0.202
0.831

Ref.
0.642

Ref.
0.058

< 0.001

1.104
NA

0.101
NA

< 0.001
NA

Ref.
-0.127

Ref.
0.086

0.139

-0.122
NA

0.112
NA

0.273
NA

NA=not applicable; SE=standard error; MME=morphine milligram equivalent;
AIC=Akaike information criterion; BIC=Bayesian information criterion.
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Differential homophily
Estimate
SE
NA
NA
-0.060
0.006

P-value
NA
< 0.001

FIGURES

Patients
n=222,513

Schedule II-IV opioid prescription in 2015

Patients
n=222,464

Patients
n=222,442

Patients
n=209,716

Providers
n=16,548

Excluding compounding products
Providers
n=16,544

Prescriptions
n=808,963

Excluding Buprenorphine products
Providers
n=16,544

Excluding institutional DEA prescribers
Providers
n=16,540

Prescriptions
n=809,195

Prescriptions
n=808,914

Prescriptions
n=778,515

Excluding providers who prescribed to < 6 patients per year

Patients
n=196,933

Providers
n=4,100

Prescriptions
n=748,202

1 of 3 opioid types/1payment method/≥6 opioid Rx fills per year
Patients
n=10,100

Providers
n=2,262

Prescriptions
n=124,963

Excluding patients who saw < 3 providers or used < 3 pharmacies per year
Patients
n=372

Providers
n=746

Prescriptions
n=5,274

Figure 1. Study Sample Selection Flowchart showing number of patients, providers, and
opioid prescriptions with exclusion criteria
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Patients

A
1
2
3
4
5
6

Providers
X
Y
Z
1
1
0
1
0
0
0
1
0
0
1
1
0
1
1
0
0
1

B
1
2
3
4
5
6

AAT

1
2
1
1
1
1
0

2
1
1
0
0
0
0

3
1
0
1
1
1
0

4
1
0
1
2
2
1

5
1
0
1
2
2
1

6
0
0
0
1
1
1

Figure 2: Matrix illustration of the construction of a simple network. Bipartite
incidence matrix, A (left panel) shows the relation “prescribed opioid analgesic(s) to”
and the one-mode projection adjacency matrix B (right panel) shows the providersharing relationships between patients. One-mode projection of the bipartite network
is obtained by post-multiplying the matrix A by its transpose, AT.

Figure 3. Schematic illustrating a projection from a two-mode to a one-mode network.
Bipartite network graph of “prescribed opioid analgesic(s) to” relation for 3 providers
(X, Y, Z) and 6 patients (1-6) [left panel] and a unipartite network graph of “shares a
provider with” relation for 6 patients (right panel).
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Figure 4. Four depictions of the full patient network: (a) Full network with few isolates
and clusters; (b) clustering by age category; (c) clustering by sex; and (b) clustering by
opioid type.
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Figure 5. Four depictions of the largest connected component: (a) The largest connected
component with few clusters; (b) clustering by age category; (c) clustering by sex; and
(b) clustering by opioid type.
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Figure 6: Ego-centric network around the most influential patient (# 24) identified by
degree, closeness, and betweenness centrality measures. This ego-centric network is
subgraph corresponding to the most influential patient with his or her immediate
neighborhood.
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Figure 7. Degree distribution in original scale (top panels), log-log scale (middle panels),
and the average neighbor degree versus vertex degree on a log-log scale (bottom panels)
for complete network (left) and its largest connected component (right).
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Figure 8: Plots of degree and shared partnerships (DSP and ESP) in the largest connected
component of the network (left) and a randomly generated network of the same size and
density (right). Abbreviations: DSP=dyad-wise shared partners, ESP= edgewise shared
partners, GC=giant component.
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Figure 9: Number of triangles in 1000 networks simulated based on the null model of the
largest connected component of the network.
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FUTURE RESEARCH WORK
In the future we plan to incorporate structural properties of the observed opioid network
as model covariates thereby allowing the observed network to be conditioned on
observed degree distribution and level of transitivity. This will be implemented in R
using a Bayesian approach which exhibits better convergence properties than nonBayesian method used in this analysis. We also plan to analyze corresponding providerand pharmacy-based networks where connections between providers or pharmacies
represent patient-sharing. These analyses will also use centrality measures to identify the
most influential providers and pharmacies and evaluate whether patterns of opioid
prescribing or dispensing vary by communities in the network.
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TECHNICAL APPENDIX
A. NETWORK CHARACTERIZATION AND MEASUREMENTS
This Technical Appendix provides statistical formulations of key terms used in this
thesis. The notations and definitions are adapted from Kolaczyk.1 In general, let
uppercase letters denote random variables and lowercase denote realizations of those
random variables. We assume the observed network is fixed and does not vary over time.
We also assumed that we ascertained the full network sample.

Defining a Network: A graph G = (V, E) is a mathematical structure consisting of a set
V of vertices or nodes and a set E of edges or links, where elements of E are unordered
pairs {u,v} of distinct vertices u,v ∈ V for an undirected graph. The number of vertices Nv
= |V| and the number of edges Ne = |E| are called the order and size of the graph G,

respectively. A graph H = (VH, EH) is a subgraph of another graph G = (VG, EG) if VH ⊆
VG and EH ⊆ EG. An induced subgraph of G is a subgraph
pre-specified subset of vertices and

=( ,

), where

⊆ V is a

⊆ E is the collection of edges to be found in G

among that subset of vertices. A simple graph has no edges for which both ends connect

to a single vertex (i.e., no loops) and no pairs of vertices with more than one edge
between them (i.e., no multi-edges). Two vertices u,v ∈ V are said to be adjacent if joined

by an edge in E, and two edges e1,e2 ∈ E are adjacent if joined by a common endpoint in

V. A vertex v ∈ V is incident on an edge e ∈ E if v is an endpoint of e.

A network therefore consists of a set of nodes and the relationships (ties, links,

edges, connections) among them. The relationship can be directed or undirected and
dichotomous (present or absent). All pairs of nodes in a network are dyads while all sets
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3 nodes form triads. These dyads and triads can be linked or unlinked. A group of k
nodes taking a star format with a node at the center linked to all others in the group is
called k-star. An undirected network has two types of dyads (null or present) and four
types of triads defined by the number of connected edges (0, 1, 2 or 3) and may have a 3star, 4-star, and 5-star formats. We also distinguish edgewise shared partnership (ESP)
and dyad-wise shared partnership (DSP). A DSP is a linked or unlinked dyad where both
members of the dyad are linked to a third network member. ESP is a subset of DSP with
a linked dyad in which both members of the dyad also have a link to a third network
member. The distribution of ESP in a network shows how many dyads have one shared
partner, two shared partners, and so on. Similarly, the distribution of DSP shows the
number of dyads in the network with one shared partner, two shared partners, and so on.
A bipartite network is a graph G = (V, E) such that the vertex set V may be
partitioned into two disjoint sets, say V1 and V2, and each edge in E has one endpoint in
V1 and the other in V2. Specifically, a graph G1 = (V1, E1) may be defined on the vertex
set V1 by assigning an edge to any pair of vertices that both have edges in E to at least
one common vertex in V2. Similarly, a graph G2 may be defined on V2.
Several notions are related to the concept of movement around a graph. A walk on a
graph G, from v0 to vl, is an alternating sequence {v0, e1, v1, e2, . . . ,vl−1, el , vl}, where the
endpoints of ei are {vi−1, vi}. The length of this walk is said to be . A trail is a walk
without repeated edges and a path is a trail without repeated vertices. A vertex v in a
graph G is said to be reachable from another vertex u if there exists a walk from u to v.
The graph G is said to be connected if every vertex is reachable from every other. A
component of a graph is a maximally connected subgraph. Geodesic (distance) is the
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length of the shortest path(s) between the vertices (which we set equal to infinity if no
such path exists). The diameter of the graph is the value of the longest distance in a
graph.
Algebraic graph theory has several applications in social network analysis. The
connectivity of a graph G may be captured and stored in an Nv×Nv binary, symmetric,
adjacency matrix A with entries:

Ai j =
where A is non-zero for entries whose row-column indices correspond to vertices in G
joined by an edge, and zero, for those that are not. The row sum Ai+ = Σj Ai j is equal to
the degree di of vertex i. and by symmetry, Ai+ = A+i. The structure of a graph G may
also be captured in an Nv×Ne binary, incidence matrix B with entries:

Suppose that G = (V, E) is a graph corresponding to an observed social network among
individuals i ∈ V, with a social tie between individuals i, j ∈ V indicated by an edge {i, j}

∈ E. Let Yi j = Yji = 1 if {i, j} ∈ E, and zero if not. Y = [Yi j] is the adjacency matrix for G,

and treated as a random matrix.

Modularity: The process of community detection can be approached as an optimization
problem using computational algorithms developed for studying similar networks.2,3 The
algorithm detects subgroups within networks that are more inter-connected than would be
expected by chance alone.3-5 In our example, each provider was assigned to a single
community, such that communities are comprised of distinct, non-overlapping groups of
providers in the network. The null model adjusts for node degree so that patients with
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high nodal degree are more likely to be connected than those with low nodal degree
thereby maintaining the expected degree distribution of the network.4 The optimization
process involves the maximization of the quantity:
,
where

is nonzero if and only if node

and

are connected by a tie, and its value

quantifies the number of providers the two patients share;

is the degree of node ,

the number of edges in the network (or their total weight in weighted networks),
community assignment of node , and

is

is the

is the Kronecker delta which is equal to 1

if the arguments are identical, otherwise it is zero. We used the greedy optimization
method which has been shown to perform well for a variety of networks6.

Centrality measures: A patient that is connected to many other patients in a network is
in a prominent or influential position within the network. This simplest measure of
centrality is based on the notion that a patient with more direct connections in the
network is more influential than one with fewer or no connections at all. The degree dv of
a vertex v, in a network graph G = (V, E), is the number of edges in E incident upon v,
that is, at distance one and mean degree is the average degree of all patients in the opioid
network. Vertex degree is arguably the most widely used measure of vertex centrality. In
our setting, the patients with higher degrees are more central because in many social
settings people with more connections tend to be more influential. A patient’s degree is
the total number of other patients within the network who are connected to the patient
through provider sharing. Degree centrality we can be standardized by dividing by the
maximum possible value of |V|-1.
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Given a network graph G, we define fd to be the fraction of vertices v ∈ V with degree dv

= d. The collection {fd}d≥0 is called the degree distribution of G. The degree distribution
provides a summary of the connectivity in the graph.
Another notion of a ‘central role in the network’ is that a vertex be ‘close’ to many other
vertices. The standard approach, introduced by Sabidussi, is to let the centrality vary
inversely with a measure of the total distance of a vertex from all others.7
cl(v) =

,

where dist(v,u) is the geodesic distance between the vertices u,v ∈ V. Using this

formulation, the more central a node is, then the lower its total distance to all other nodes.
For comparison across networks and with other centrality measures, this measure is
normalized or standardized to lie in the interval [0,1], through multiplication by a factor
Nv−1.
Betweenness centrality is based upon the perspective that importance relates to
where a vertex is located with respect to the paths in the network graph. If we assume
those paths as the routes by which communication and other exchanges takes place,
vertices that sit on many paths are likely more critical to the communication and other
dissemination processes. Betweenness centrality measures are aimed at summarizing the
extent to which a vertex is located ‘between’ other pairs of vertices. This is defined as the
proportion of times the provider lies on the shortest paths in the network. A patient is
central in the network if he/she is located between many non-adjacent patients on their
geodesics (shortest) paths. The most commonly used betweenness centrality, introduced
by Freeman,8 is defined as
cB(v) =

,
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where σ (s, t|v) is the total number of shortest paths between s and t that pass through v,
and σ (s, t) = Σvσ (s, t|v). In the event that shortest paths are unique, cB(v) just counts the
number of shortest paths going through v. This centrality measure can be normalized
through division by a factor of (Nv−1)(Nv−2)/2.

Network cohesion: The definition of network cohesion depends on the context.
Generally, network cohesion refers to the extent to which subsets of nodes are connected
to each other to form triads, components, clusters, and communities.
Network density: For a graph G with no self-loops and no multiple edges, the density of a
subgraph H = (VH, EH) is
den(H) =
The value of den(H) lies between zero and one.
Clustering coefficient and transitivity: A triangle is a complete subgraph of order three. A
connected triple is a subgraph of three vertices connected by two edges. A measure of the
frequency with which connected triples form closed triangles provides some indication of
the extent to which edges are ‘clustered’ in the graph. Let

denote the number of

triangles in G into which v ∈ V falls, and τ3(v), the number of connected triples in G for

which the two edges are both incident to v. The local clustering coefficient, den(Hv) can
for those vertices v with τ3(v) > 09. The

be re-expressed as cl(v) =

corresponding clustering coefficient for G takes the form:
cl(G) =

,

where V’ ⊆V is the set of vertices v with dv ≥ 2.
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The clustering coefficient is the ratio of total the number of connections that exist among
neighbors of the patient in the network to the total number of potential connections that
could exist if they were completely connected. It is used to describe the extent to which
network neighbors of a particular patient are directly connected to each other and
interpreted as the probability that any two randomly selected neighbors of a particular
patient in the network are connected to each other.
Assortativity and mixing: Assortative mixing is the selective linking among
vertices, according to a certain characteristic(s), and measures that quantify the extent of
assortative mixing in a given network have been referred to as assortativity coefficients.
Suppose that each vertex in a graph G can be labeled according to one of M categories.
Let fij be the fraction of edges in G that join a vertex in the ith category with a vertex in
the jth category; denote the ith marginal row and column sums of the resulting matrix f by
fi+ and f+i, respectively. We then define the assortativity coefficient ra to be
ra =

.

The value ra is equal to zero when the mixing in the graph is no different from that
obtained through a random assignment of edges that preserves the marginal degree
distribution. Similarly, it is equal to one when there is perfect assortative mixing (i.e.,
when edges only connect vertices of the same category). When the mixing is perfectly
disassortative, the value takes its minimum value, that is, every edge in the graph
connects vertices of two different categories.
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B. The Exponential Random Graph Model (ERGM)
A discrete random vector Z is said to belong to an exponential family if its probability
mass function may be expressed in the form
,
where θ ∈

is a p×1 vector of parameters, g(·) is a p-dimensional function of z, and ψ(θ

) is a normalization term, ensuring that Pθ (·) sums to one over its range. The class of

discrete exponential families includes many familiar distributions, such as the binomial,
geometric, and Poisson. In the case of continuous exponential families, where an
analogous form of the equation holds for probability density functions, examples include
the Gaussian and chi-square distributions.
Consider G = (V, E) as a random graph. Let Yij =Yji be a binary random variable
indicating the presence or absence of an edge e ∈ E between the two vertices i and j in V.

The matrix Y = [Yij] is thus the (random) adjacency matrix for G. Denote by y = [yij] a
particular realization of Y. An exponential random graph model is a model specified in
exponential family form for the joint distribution of the elements in Y. An ERGM takes
the form
Pθ (Y = y) =

,

where the following conditions hold:
(i) each H is a configuration is a set of possible edges among a subset of the vertices in G;
(ii) gH(y) =

, and is either one if the configuration H occurs in y, or zero,

otherwise;
(iii) a non-zero value for θH means that the Yij are dependent for all pairs of vertices {i, j}
in H, conditional upon the rest of the graph; and
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(iv) κ =κ(θ ) is a normalization constant, where
κ(θ) =

.

The summation in the previous equation is over all possible configurations H. Note that
this model implies a certain (in)dependency structure among the elements in Y.
Generally, such assumptions specify that the random variables {Yij}(i,j)∈A are independent
of

, conditional on the values of

, for given index sets A ,B, and

C.
Bernoulli or Simple Random Graph: The simple random graph model randomly
distributes ties or connections among network members based on the same specified
probability.10,11 Network density or the probability of a tie occurring is the proportion of
observed ties out of all possible ties:
den(H) =
This calculation assumes that ties are independent and identically distributed and ignores
the attributes of network members that may influence the probability of a tie. Suppose we
specify that, for any given pair of vertices, the presence or absence of an edge between
that pair is independent of the status of possible edges between any other pairs of
vertices. That is, for each pair {i, j}, we assume that Yij is independent of
{

}

, for any

{i, j}. This assumption implies that θH = 0 for all configurations H involving

three or more vertices. In this case, the only relevant functions gH are those of the form:
gH(y) = gij(y) = yij, and the ERGM reduces to
Pθ (Y = y) =

,

This implies that each edge {i, j} is present in the graph independently with probability
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pij = exp(θij)/[1+exp(θij)] .
However, this entails a model with

parameters, which is likely far too parameterized

for many data sets.
In order to reduce the total number of parameters, it is common to impose an
assumption of homogeneity across certain vertex pairs. For example, assuming
homogeneity across all of G (i.e., θij ≡θ , for all {i, j}) yields
Pθ (Y = y) =

,

where L(y) = Σi,j yij = Ne is the number of edges in the graph. In this case, the Bernoulli
random graph model is recovered, with p = exp(θ )/[1+exp(θ )] .
Assumptions of complete independence among possible edges are largely
untenable in practice. In general, Bernoulli-like random graphs lack the ability to
reproduce many of the most basic structural characteristics observed in most real-world
networks. However, the simple random graph model provides a baseline to compare with
more complex models and assess improvements in model fit using simulation methods.
Markov Random Graphs: Frank and Strauss introduced the notion of Markov
dependence for network graph models, which specifies that two possible edges are
dependent whenever they share a vertex, conditional on all other possible edges, and
independent if they do not.12 That is, the presence or absence of {i, j} in the graph will
depend upon that of {i,k}, for a given k

j, even given information on the status of all

other possible edges in the network. A random graph G arising under Markov
dependence conditions is called a Markov graph. This model was extended by assuming a
more general conditional dependence among ties in a network (i.e., two connections are
conditionally dependent if the conditional probability that both connections exist in the
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network does not equal the product of their marginal conditional probabilities, given all
other network ties.) Under an assumption of homogeneity, Frank and Strauss showed that
G is a Markov graph if and only if Pθ (·) may be expressed as
Pθ (Y = y) =

,

where S1(y) = Ne is the number of edges, Sk(y) is the number of k-stars, for 2 ≤ k ≤ Nv−1,
and T(y) is the number of triangles. The statistics Sk in and T, can be correlated. We see
from the definitions of the statistics Sk and T that Markov dependence results are
explicitly parameterized to account for some effects of transitivity.
In practice, it is common to include star counts Sk no higher than k=2 or at most
k=3, by setting

=…=

=0. This often leads to model degeneracy. Inclusion of a

large number of higher order terms does not solve this problem. Partial conditional
dependence assumption has been proposed to address issues of degeneracy. For example,
Snijders et al proposed a solution by imposing a parametric constraint of the form
upon the star parameter, for all k ≥ 2, for some

larger than one.13 This

tactic combines all k-star statistics Sk(y), for k ≥ 2, into a single alternating k-star statistic
of the form

and weighting that statistic by a single parameter θAKS that takes into account the star
effects of all orders simultaneously. The alternating signs allow the counts of k-stars of
successively greater order to balance each other, rather than simply ballooning. We often
assume that dependence between ties that do not share a node is due to the presence of
other ties in the network.14 To account for this partial conditional dependence, three non69

linear terms are often added to the model: geometrically weighted degree (GWD),
geometrically weighted DSP (GWDSP), and geometrically weighted ESP (GWESP). The
statistic AKSλ (y) is a linear function of GWD count. The GWD term is designed to
account for the decreasing degree distribution in observed networks while GWESP term
is designed to account for clustering in observed networks. Finally, the GWDSP term
accounts for the number of dyads with shared partners, often found within clusters in the
network.

C. Constructing the Exponential Random Graph Models
Several packages are available for estimating network models. Our analysis was
conducted in R-statnet, a suit of packages for building ERGMs in R. We first employed
the null model which corresponds to the simple random graph model and can be written
as:
.
The model was estimated by maximum likelihood estimation and served as a comparator
for assessing model fit as more useful and complex models were constructed.
Adding attributes: We first considered whether the addition of node attributes influenced
the likelihood of a tie in the network. These nodal attributes accounted for the
characteristics of each individual network member. To examine the effects of these
attributes on the likelihood of a tie, these attributes were added to the model as main
effects. The null and alternate hypotheses are:
H0: There is no association between node attribute and the likelihood of a patient to form
ties.
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Ha: There is association between node attribute and the likelihood of a patient to form
ties.
In statnet, categorical and continuous main effects are added using nodefactor and
nodecov(), respectively. Nodefactor main effect term adds multiple statistics to the model
output, each corresponding to the number of times a node with the specified attribute is at
one end of an edge. The

corresponding to a categorical node attribute can be

summarized as follow:

The reference group which is omitted in the output can be changed using the base
argument.
The nodecov main effect term adds one network statistic to the output that sums the
attribute of interest for the two nodes in a dyad.
Interaction terms for nodal attributes to account for the attributes of both members of a
dyad in the network. Homophily interaction terms were included in the model using
nodematch. Differential homophily was requested by specifying diff=TRUE after the
name of the attribute in a nodematch term. The homophily change statistics is defined as:

And the differential homophily change statistics is as:

A potential limitation is that models that include the interaction terms are dyadic
independence models which assume that each dyad is independent of all other dyads in
the model.
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Model fit and diagnostic assessments: Model fit assessment involves a systematic
examination of how well the model actually captures the observed network structures
being modeled. We compared models using the statistical measures of log-likelihood and
the related deviance (-2LogL), the Akaike information criterion (AIC), or the Bayesian
information criterion (BIC). The log-likelihood is calculated by summing the difference
between predicted probabilities of

and the observed value of

The deviance is a measure of lack of fit and a larger deviance indicates a greater the lack
of fit. The deviance gets smaller as more parameters are added to the model. The AIC and
BIC account for this by penalizing models with more parameters that do not improve the
model fit.
AIC = Deviance + 2p,
BIC = Deviance + p*2ln(N),
where p is the number of parameters and N is the network size.
Both values of the AIC and BIC were used to compare nested and non-nested models.
These measures of model fit were developed for the analysis of data that are assumed to
meet the independence of observation assumption. The null, main effect, and homophily
models which assume dyadic independence were compared using deviance, AIC, and
BIC. Models to account for non-uniform degree distribution and transitivity resulting
from complex of dependence in observed social networks GWD, GWESP, and GWDSP
were not evaluated in this analysis.
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